Abstract Pathologic complete response following neoadjuvant therapy (NAT) is used as a short-term surrogate marker of eventual outcome in patients with breast cancer. Analyzing voxel-level heterogeneity in MRI-derived parametric maps, obtained before and after the first cycle of NAT (n ¼ 33), in conjunction with receptor status, may improve the predictive accuracy of tumor response to NAT. Toward that end, we incorporated two MRIderived parameters, the apparent diffusion coefficient and efflux rate constant, with receptor status in a logistic ridge-regression model. The area under the curve (AUC) and Brier score of the model computed via 10-fold cross validation were 0.94 (95% CI: 0.85, 0.99) and 0.11 (95% CI: 0.06, 0.16), respectively. These two statistics strongly support the hypothesis that our proposed model outperforms the other models that we investigated (namely, models without either receptor information or voxel-level information). The contribution of the receptor information was manifested by an 8% to 15% increase in AUC and a 14% to 21% decrease in Brier score. These data indicate that combining multiparametric MRI with hormone receptor status has a high likelihood of improved prediction of pathologic response to NAT in breast cancer.
Combining multiparametric MRI with receptor information to optimize prediction of pathologic response to neoadjuvant therapy in breast cancer: preliminary results
Introduction
Neoadjuvant therapy (NAT) not only provides a way to decrease tumor size to allow for breast conservation therapy but also is an excellent opportunity to observe tumor sensitivity to a particular regimen. If the primary tumor responds, any systemic micrometastases may also be sensitive to the same therapy. 1 Conversely, if the primary tumor is unresponsive, then the treatment can be changed to another, potentially more effective approach. A number of preoperative systemic regimens are available, some targeting specific cancer subtype according to the National Comprehensive Cancer Network (NCCN). For example, in patients with human epidermal growth factor receptor 2 (HER2) negative disease, these include dose-dense AC (doxorubicin/ cyclophosphamide) and dose-dense AC followed by weekly paclitaxel or TC (docetaxel/cyclophosphamide). In patients with HER2 positive disease, AC followed by TH +/− P (doxorubicin/ cyclophosphamide followed by paclitaxel and trastuzmab with or without pertuzumab) or TCH +/− P (docetaxel plus carboplatin/trastuzumab with or without pertuzumab) are available. Numerous other regimens are also available (see NCCN guidelines for a more complete listing, Ref. 2) . The development of a method used to predict response early in the course of NAT would allow individuals to receive a treatment tailored to their specific agents. Unfortunately, evaluating the effectiveness of NAT currently requires a period of 3 to 5 months as described in NCCN guidelines, during which time one may see the potential use of ineffective and harmful agents. We propose that integrating quantitative magnetic resonance imaging (MRI) data with hormone receptor status can enable the accurate prediction of a treatment response after an individual patient has received a single cycle of therapy.
The response of breast tumors to NAT is currently evaluated by large changes in tumor size as measured by a physical exam, conventional MRI, and/or ultrasound, but these methods generally do not show whether a tumor is responding until the patient has received several treatment cycles. To overcome this hurdle, many investigators have applied diffusion-weighted MRI (DW-MRI) and dynamic contrast-enhanced MRI (DCE-MRI) to provide quantitative and complementary information in monitoring the response of breast tumors to NAT. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] DW-MRI is sensitive to the thermally induced, random motion of water molecules in tissue. The rate of diffusion in tissue is described by an apparent diffusion coefficient (ADC), which can be measured by established DW-MRI methods. [18] [19] [20] [21] In controlled experiments, the variations in ADC have been shown to correlate inversely with tissue cellularity. [22] [23] [24] [25] [26] In DCE-MRI, images are acquired before and after a contrast agent is injected into a peripheral vein. Each image in this dynamic series corresponds to one time point, and temporal intensity variation for each voxel can then be analyzed with a pharmacokinetic model to estimate physiological parameters such as the contrast agent transfer constant (K trans related to vessel perfusion and permeability), the extravascular extracellular volume fraction (v e ), the plasma volume (v p ), and the efflux rate constant (k ep ¼ K trans ∕v e ). [27] [28] [29] [30] [31] [32] [33] [34] An emerging area of interest is predicting response to NAT using averaged quantitative, MRI-derived parameters over a region of interest (ROI) in combination with clinical variables. 35 Importantly, other studies have demonstrated that combining voxel-level DCE-and DW-MRI 36 and ROI-averaged multimodal MR and/or PET/CT 7,9 metrics (e.g., k ep from DCE-MRI, ADC from DW-MRI, and maximum standardized uptake value from PET/CT) enhances the predictive accuracy of the response to the first cycle of NAT, compared with that of each modality alone. Moreover, it has been demonstrated that breast cancer subtypes can significantly affect the prediction of tumor response to NAT. [37] [38] [39] [40] This prompted research to include breast cancer subtype, along with the clinical variables and voxel-level quantitative parameters derived from DCE-and DW-MRI as the major predictors in the NAT response model.
During the past 15 years, breast cancer classifications have evolved from those based entirely on histopathology to those based on gene expression profiling. 41 In practice, cancer subtypes can be determined either directly via multigene assays or indirectly using immunochemistry. The following subtypes are usually defined: luminal A [estrogen receptor (ER) and/or progesterone receptor (PR) positive, HER2 negative], luminal B (ER and/or PR positive, HER2 positive), HER2 (ER negative, PR negative, and HER2 positive), and basal like (ER negative, PR negative, HER2 negative, i.e., triple negative). 38 For luminal B and HER2 molecular subtype breast cancers, it has been shown that preoperative MRI can help identify multifocal and/or multicentric disease and lymph node involvement. 42 Given that the selection of treatment for breast cancer patients could be guided by molecular subtypes, we hypothesized that including information on the molecular subtypes would improve the predictive ability of our model.
Herein, we proposed a data-fusion approach via a logistic ridge-regression model, which could enhance predictive ability of MRI-derived quantitative variables for early detection of a breast cancer patient's response to NAT using the patient's hormone receptor information along with clinical information. For baseline comparison, we also employed a more conventional predictive model based on response evaluation criteria in solid tumors (RECIST) and a previously established model that did not include information on receptor status. 36 We assessed the predictive power of each model in terms of the area under the receiver operator curves (i.e., AUCs) and Brier scores computed via 10-fold cross validation (CV).
Methods
Our previous study 36 demonstrated that including both voxellevel k ep and ADC in a prediction model could enhance predictive ability of tumor response to NAT by employing redundancy analysis and logistic ridge regression. The same approach was employed to rigorously assess the contribution of hormone receptor information in prediction models via 10-fold CV in this work. Moreover, the contribution of both voxel-level k ep and ADC was assessed, compared with RECIST and clinical information, which was not addressed in the previous study.
Patient Population and Magnetic Resonance
Imaging Data
All patients signed consent forms prior to enrollment. This study was approved by Vanderbilt University Institutional Review Board. Breast cancer patients (n ¼ 33) undergoing neoadjuvant chemotherapy (see Table 1 In this study population, 12 patients exhibited pCR and 21 patients achieved non-pCR. All patients had histologically documented invasive breast cancer at least 1 cm in the longest dimension with a sufficient risk of recurrence, to warrant the use of NAT. This risk was determined by the treating oncologist using pretreatment pathologic characteristics including tumor size, nodal status, grade, ER, PR, Ki-67, and HER2 status as measured by immunohistochemistry test on a patient's biopsy sample. In particular, HER2 was scored as positive with the immunohistochemical staining score of 3+ or 2+ and the amplification ratio of ≥2.2 on fluorescence in situ hybridization. 43 Estrogen and PR status was scored as positive when at least 1% of tumor cells showed positive nuclear staining of any intensity. Receptor status was considered negative if <1% of tumor cells showed staining of any intensity. 44 A full description of patients, MRI data acquisition, image analysis methods to derive k ep and ADC, and the registration of longitudinally acquired parametric maps can be found in Ref. 36 . Note that the registration of longitudinally acquired parametric maps [45] [46] [47] [48] was crucial for obtaining changes at the voxel-level for ADC and k ep .
Statistical Analysis
As described in Ref. 36 , ADC and k ep data for each voxel in each tumor slice were acquired from 33 patients before (t 1 ) and after (t 2 ) the first cycle of NAT. These data were combined with tumor grade and age information to predict tumor response at the completion of NAT. Patients were identified as pCR if there was an absence of viable tumor cells in the primary tumor bed or lymph nodes at the time of surgery. Otherwise, the patient was identified as a nonresponder. For both k ep and ADC, the subsets of voxels that displayed an increase in k ep and a decrease in ADC from t 1 to t 2 were subjected to a redundancy analysis 49 to select a set of nonpredictable variables (defined in Appendix A). The redundancy analysis was employed after dividing the voxel-based parameter values (e.g., ADC values in the subset defined in the previous sentence) into 20 equal bins (i.e., min, 5th, . . . , 95th, max). The percentile values selected via the redundancy analysis (please see Appendix A for details) were employed as explanatory variables in subsequent logistic ridge-regression models. Due to the small number of patients (n ¼ 33) compared with the number of explanatory variables in logistic regression models, we employed logistic ridge-regression models to avoid overfitting. 50 In addition to the MRI data, we used binary hormone receptor status measured at t 1 as covariates in the prediction models; i.e., ER ¼ 0 or 1, PR ¼ 0 or 1, and HER2 ¼ 0 or 1, where 0 indicates a negative and 1 indicates a positive expression. In each model, pCR (0 = nonresponder and 1 = responder) serves as the binary outcome variable, whereas the selected percentiles of k ep and ADC and hormonal receptor status information were explanatory variables in conjunction with tumor grade and patient age. We also added the mean of each parameter within an ROI as explanatory variables into the model, which would be major explanatory variables when applied voxellevel information is not available. Therefore, the voxel-clinicalreceptor (VCR) model is expressed as follows:
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where h kepi and h ADCi are the i'th percentiles for k ep and ADC, respectively, M kep and M ADC denote the ROI-mean of k ep and ADC, respectively, ER, PR, and HER2 denote the corresponding hormone receptor status (binary), age and tumor denote the patient age (continuous) and tumor grade (continuous), and β's are regression coefficients. For comparisons, five other models were analyzed including (1) In each logistic ridge regression, the tuning parameter associated with the penalty term (sum of squared regression coefficients), which controls the contribution of the penalty term to the cost function (sum of the squared residuals), was estimated as described in Ref. 51 . Theses analyses were all performed in R Statistical Software version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria). The performance of the VCR, RCR, CR, VC, RC, and CO models was compared in terms of the AUC and Brier scores computed via 10-fold CV. 52 The statistical significance of the difference in AUCs and Brier scores estimated via 10-fold cross validation was investigated by generating a bootstrap distribution of the difference with 300 replicates. To assess the contribution of hormone receptor information, we computed the following differences for AUC: (1) AUC of VCR-AUC of VC, (2) AUC of RCR-AUC of RC, and (3) AUC of CR-AUC of CO. We also assessed the contribution of voxel-level information to the prediction of pCR in addition to the contribution of hormone receptor information by computing the following differences for AUC: (4) AUC of VCR-AUC of RCR and (5) AUC of VCR-AUC of CR. A positive difference for each comparison implied that the first model outperformed the second model in terms of the AUC. The contributions of both the receptor information and voxel-level information were assessed using Brier scores. For each comparison, we used Brier scores in lieu of AUC values. Note that a negative value of the difference in Brier scores indicated that the first model outperformed the second model in terms of predictive power. P-value associated with each comparison was computed using bootstrap-estimated standard deviation (t-test).
10-Fold Cross Validation
To assess predictive power of each model corrected for overfitting, we computed AUC and Brier score via 10-fold CV. After randomly partitioning the data into 10 equally sized subgroups, each model was estimated using only nine subgroups and then validated against the remaining subgroup. After each of the 10 subgroups was used for validation, AUC and Brier score were evaluated, which completed one round of cross validation. To reduce variability, we repeated 100 rounds of 10-fold CV and averaged AUCs and Brier scores over 100 rounds, resulting in estimated AUC and Brier score for each model. We then repeated this procedure (i.e., from random partitioning to averaging AUCs and Brier scores over 100 rounds) 300 times to construct 95% confidence intervals (CI) for the estimated AUC and Brier score, with randomly resampled data with replacement. Details are described in Appendix B and Fig. 5 . This approach was preferred over the leave-one-out cross validation, which tends to inflate the variance of AUC (or Brier score) estimates. 53 Journal of Medical Imaging 011015-3 Jan-Mar 2018 • Vol. 5 (1) 3 Results
Registration
In Fig. 1 , representative k ep (a-c) and ADC (d-f) parametric maps are superimposed on the postcontrast DCE-MRI data at baseline (a and d), and after the first (b and e) and last cycles of NAT (c and f) for a patient achieving pCR. Longitudinally acquired parametric maps at three time points were transformed into common space using the previously developed method. 45, 54 Similar data for a patient with a residual disease (i.e., a non-pCR patient) are shown in Fig. 2 .
Note that for the patient achieving pCR, the mean k ep within the tumor ROI decreased from 0.42 to 0.31 min −1 between the pre-and postfirst cycle of NAT, whereas for a patient not achieving pCR, k ep increased from 0.26 to 0.32 min −1 between these same time points. The mean ADC increased from 1.47 to 1.75 mm 2 ∕s × 10 −3 between the first two time points for the same complete responder as shown in Fig. 1 , while no noticeable change in mean ADC was observed for the nonpCR patient shown in Fig. 2 . Both the ROI-level mean k ep and ADC values were not available for the pCR patient after all cycles of NAT because there were no residual tumor voxels. 
Hormone Receptor Status
In Table 1 , the molecular subtypes of 33 patients are summarized. Among the 33 patients, 9 (27%), 6 (18%), 8 (24%), and 10 (31%) patients are classified into luminal A, B, HER2, and basal subtype, respectively. As molecular subtypes can be determined either directly via multigeneassays or indirectly using immunochemistry, we elected to use receptor status to define the molecular subtype since this was available for all patients. We employed hormone receptor status as a covariate in each model; importantly, the effect of each hormone receptor status on pCR status can be directly assessed by this approach.
Area Under the Curve and Brier Score via 10-Fold Cross Validation
In Table 2 , the AUCs and Brier scores estimated via 10-fold CV from the six logistic ridge-regression models are reported along with the corresponding 95% CIs. The AUC from the VCR model (AUC ¼ 0.94) outperforms all the other AUC values reported in Table 2 . In particular, it outperforms the VC model, which achieved an AUC of 0.87, (i.e., about an 8% increase in the AUC compared with the VC model). The additional contribution of hormone receptor information was assessed by comparing the AUCs of the VCR, RCR, and CR models with those of the VC, RC, and CO models, achieving increases in AUC of 8%, 14%, and 15% for each comparison, respectively. It is noteworthy that the AUC of VCR also outperforms the RCR and CR models by 16% and 22%, respectively, due to using voxel-level information in addition to the hormone receptor information. Moreover, the VCR model achieves the smallest Brier score 0.11, indicating that the VCR model can predict pCR more accurately than the VC (Brier score ¼ 0.14), RCR (Brier score ¼ 0.16), RC (Brier score ¼ 0.20), CR (Brier score ¼ 0.18), and CO (Brier score ¼ 0.21). The additional contribution of the receptor information was assessed by comparing the Brier scores of the VCR, RCR, and CR models with those of the VC, RC, and CO models achieving reductions in the Brier scores of 21%, 20%, and 14%, respectively, for each comparison. Note that the Brier score of VCR also outperforms RCR and CR models (31% and 39% improvements, respectively) due to using voxel-level information in addition to the hormone receptor information. Therefore, incorporating hormone receptor information (or molecular subtype) improves both the AUC and Brier score associated with predictive performance of the model. The bootstrap distribution of the differences in AUCs between VCR and VC, and between RCR and RC, is shown in Fig. 3 for illustration purpose. The area of the shaded region in Note that the models with additional receptor information are 84% to 94% more likely to outperform the corresponding models without the receptor information in terms of AUC. Moreover, the models using voxel-level information (i.e., VCR) would be 98% or 99% more likely to outperform the RCR and CR models (i.e., the models do not use voxel-level information), respectively. The bootstrap distribution of the differences in Brier scores between VCR and VC, and between RCR and RC, is shown in Fig. 4 . The area of the shaded region in Fig. 4 (i.e., 0.03 to 0.13) indicates that the Brier score resulting from VCR (RCR) is larger than that from VC (RC): the VCR (RCR) model would be 97% (87%) more likely to outperform the VC (RC) model in terms of Brier score. In addition to AUCs, we have shown that the contributions of both hormone receptor information and voxel-level information are significant as displayed in the third column of Table 3 . The p-values associated with comparisons for the differences in AUCs and Brier scores are summarized in the fourth and fifth columns in Table 3 . None of the AUC differences is statistically significant at FDR ¼ 0.1 except for the difference in Brier score between the VCR and CR models. Marginal significance is also observed for Brier score of the VCR versus the VC and RCR models. Although the 95% CIs reported in Table 2 and the p-values in Table 3 do not support statistically significant differences for each comparison, the values in the first two columns of Table 3 (Figs. 3 and 4 ) strongly suggest that the AUC and Brier scores of the VCR are likely to outperform the other models. Appendix C summarizes details on (1) the three most often chosen variables and a total number of variables chosen by redundancy analysis, (2) six estimated models with our data (n ¼ 33), including penalty parameters, and (3) summary of bootstrap distribution of ridge penalty parameters.
Discussion
It has previously been shown 36 that combining spatially heterogeneous voxel-level information of quantitative MRI-derived Table 3 The likelihood of the first model outperforming the second for each comparison in terms of AUC and Brier scores based on 10-fold CV and the p-value associated with each comparison. Prob(AUC) and Prob(Brier score) denotes the probability that the first model (e.g., VCR) outperforms the second model (e.g., VC) in terms of AUC and Brier score, respectively. The p-values associated with t -tests for difference in AUC and Brier score between two models are computed using bootstrap-estimated standard deviation. The first three comparisons assess the contribution of the hormone receptor information to the prediction of pCR, and the last two comparisons are to investigate the contribution of voxel-level information to the prediction.
10-fold cross validation
P-values Journal of Medical Imaging 011015-6 Jan-Mar 2018 • Vol. 5 (1) parameters (i.e., both k ep and ADC) with ROI-level summary information of those parameters and clinical information (i.e., patient age and tumor grade) enhances the ability to accurately predict the response of breast tumors to NAT, compared with univariate analysis with any one parameter. Moreover, there are studies proving that tumor subtypes have had an effect on the prediction of tumor response to NAT using DCE-MRI or DW-MRI. [37] [38] [39] [40] Based on these developments, we have proposed a model that integrates voxel-level MRI-derived parameters with hormone receptor status (i.e., PR, ER, and HER2) in an attempt to improve the ability to predict tumor response in breast cancer patients receiving NAT. The AUC and Brier score of the proposed model, estimated via 10-fold CV (predictors: hormone receptor status and voxel-level and ROI-level k ep and ADC along with clinical information) outperformed the VC (predictors: voxel-level and ROI-level k ep and ADC along with clinical information), RCR (predictors: RECIST along with clinical and receptor information), RC (predictors: RECIST + clinical information), CR (predictors: clinical and receptor information), and CO (predictors: clinical information only) models.
The major limitations of the current study are the modest sample size (n ¼ 33) and the lack of validation of the VCR model using an independent cohort of patients. This makes it difficult to generalize our conclusions to a population of breast cancer patients, although our initial results are very promising. Although for generalization it is imperative to have access to external sources of appropriate data to validate our findings, locating such data is quite challenging. For example, although The Cancer Imaging Archive (TCIA) is an excellent source for large imaging-based data sets, there is currently a paucity of longitudinal, quantitative, multimodal MRI data (with linked hormone receptor status) at the pre-and postone-cycle of NAT time points. Moreover, the availability of hormone receptor status is another potential limitation. In fact, to the best of our knowledge, the only appropriate data set on the TCIA is the very one analyzed in this article. The results presented in this paper speak to the importance of building publicly available data sets that include quantitative parametric maps.
Li et al. 7, 36 have shown that the combined use of two MR modalities (DCE-and DW-MRI) along with clinical and pathology data improved the prediction of response to NAT (n ¼ 33, AUC ∼ 0.87 with overfitting correction), although the studies that have employed only one of these modalities have also demonstrated utility in predicting tumor response to NAT. 13, 15 Park et al. 9 have confirmed that the integration of DW-MRI and PET/CT enhanced the ability to provide accurate predictions (n ¼ 34, AUC ¼ 0.94 without overfitting correction). With midsized data sets (n ¼ 81), Michishita and colleagues 40 have revealed that a logistic regression model that included both breast cancer subtypes and tumor morphology measured by DCE-MRI as predictors achieved an AUC of 0.83 (without overfitting correction), which outperformed the models that included only subtype or morphology alone. These results based on the small-and midsized data are consistent with our findings that combining all available information improves the predictive power of early tumor response to NAT. However, because adding more predictors tends to improve AUC regardless of the clinical relevance of the added information, it is imperative to correct for overfitting when evaluating statistical models.
In conclusion, we have presented a logistic ridge-regression model for predicting the response of breast tumors to NAT using voxel-and ROI-level k ep and ADC parameters, as well as hormone receptor status and clinical data. The predictive power of this model, measured with the AUC and Brier score, is superior to that of a model based only on RECIST and clinical data (i.e., the RC model) and a model based only on voxel-level parameter data and clinical data alone, without hormone receptor information (i.e., the VC model).
Appendix A: Redundancy Analysis
The goal of redundancy analysis with the set of 21 variables, X 1 ; X 2 ; : : : ; X 21 , is to select which are the most "nonpredictable" by the remaining variables at a given level of the coefficient of determination [in this study, we set the coefficient of determination (¼ R 2 ) threshold to be 0.9]. To achieve this, we first fit 21 multiple regression models. In each model, X i (i fixed) is the dependent variable while the other 20 (X j , j ≠ i) are the explanatory variables. When the R 2 resulting from a model is >0.9, then the dependent variable corresponding to the model is defined as predictable and removed from the set. If it is <0.9, the variable is defined as nonpredictable. This procedure is repeated until no variable can be removed from the set. The remaining nonpredictable variables are defined as the most nonpredictable and are included in our prediction models, i.e., the VC and VCR models. Note that the correlation matrix among the most nonpredictable k ep and ADC variables is available at Ref. 55 .
Appendix B

10-Fold Cross Validation
Here, we illustrate how to compute the statistic of interest via 10-fold CV to compare among models and how to construct 95% CI on the statistic of interest. Suppose that the statistic of interest is the AUC. Then
Step 1. Randomly partition the data into 10 (approximately) equally sized subsets Step 2. Use nine subsets to fit a logistic model (e.g., VCR) and compute the predicted value for each patient with the remaining subset Step 3. Repeat step 2 until each of 10 subsets is used for validation Step 4. Compute the AUC (AUC val ) using the observed pCRs and predicted pCRs Step 5. Repeat steps 1 to 4 multiple times (e.g., 100 times in this study) to reduce variability Step 6. Average over 100 CV rounds to establish the AUC cv Construct 95% CI on AUC cv
Step 7. Resample the data with replacement and then treat the resampled data as original data in the abovementioned procedure Step 8. Repeat steps 1 to 6 described above to compute AUC cv for the resampled data Step 9. Repeat steps 7 to 8 multiple times (e.g., 300 times in this study) to generate a bootstrap distribution of AUC cv Step 10. Read 2.5 and 97.5 percentile values corresponding to lower and upper limit of 95% CI, respectively.
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Steps 1 to 10 can also be applied to correct for overfitting of the Brier score for each model (Fig. 5 ).
Appendix C: Estimated Model Parameters
The three most uncorrelated variables with the remaining variables in redundancy analysis and the total number of variables selected by redundancy analysis (Table 4 ).
Summary of estimated logistic ridge-regression models and penalty parameters using our data (n ¼ 33).
Note that all the variables were centered and scaled by their standard deviations, i.e., to remove the intercept term. Note that the larger the number of predictors in a model, the better the model performs in general. Therefore, we employed logistic ridge regression to avoid overfitting for the models with a large number of predictors, e.g., the VCR and VC models. The ridge penalty parameter is proportional to the number of predictors in a model, leading to fair comparisons across models with different numbers of predictors. For each bootstrapped data set, the number of predictors in the VCR and VC models changes because it depends on the result from redundancy analysis, leading to high variation (i.e., wider range) for the ridge penalty parameters corresponding to the VCR and VC models as shown in Table 5 .
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